checkAd

     209  0 Kommentare Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application - Seite 3



    Media Contact:
    Lissa Pavluk 
    media@apellis.com
    617.977.6764

    Investor Contact: 
    Meredith Kaya 
    meredith.kaya@apellis.com
    617.599.8178 

    1Apellis data on file reflecting analysis of Colijin et al., 2016; Wong et al. 2014; Rudnicka et al., 2014; Korb et al., 2014; Piermarocchi et al., 2011; Fernandez-Arias et al., 2011; Augood et al., 2006.
    2Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta analysis. Ophthalmology 2012;119:571–580.
    3Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106–116.
    4 Lindblad AS, et al, and AREDS Research Group. Arch Ophthalmol. 2009;127(9):1168-1174.


    Seite 3 von 3




    globenewswire
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Verfasst von globenewswire
    Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application - Seite 3 WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) - Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on the …